Stock listing
Lang & Schwarz:A3C4Y0 Abbisko Cayman Limited Aktie
German listing (Lang & Schwarz) of Abbisko Cayman Limited · home listing HKEX:2256
Follow Abbisko Cayman Limited into a list and get an email when it puts out news.
Home listing price · HKEX:2256
$5.68 HKD -0.62 (-9.8%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, HKEX:2256
- Day range
- $5.64 – $6.07 HKDNov 20, 2026
- Volume
- 2.64M sharesNov 20, 2026
- Market cap
- $4.07B HKDAt the close on Nov 20, 2026 · price × 716.2M shares outstanding
- 52-week range
- $5.64 – $14.99 HKDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $12.21M HKDMedian day 1.48M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| HKEX:2256 · Home | $5.68 HKD | -0.62 (-9.8%) | 2,641,000 | $6.065 | $6.065 | $5.64 | $6.30 | Close on Nov 20, 2026 |
| Frankfurt:8ZD | €0.695 EUR | -0.010 (-1.4%) | — | €0.655 | €0.695 | €0.645 | €0.705 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · HKEX:2256 · HKD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $5.68 | -0.62 | -9.8% | $6.065 | $6.065 | $5.64 | 2,641,000 | |
| $6.30 | 0.00 | 0.0% | $6.28 | $6.34 | $6.045 | 2,095,000 | |
| $6.30 | -0.12 | -1.9% | $6.63 | $6.63 | $6.18 | 3,030,000 | |
| $6.42 | -0.37 | -5.4% | $6.70 | $6.925 | $6.31 | 1,657,000 | |
| $6.79 | -0.41 | -5.7% | $7.20 | $7.20 | $6.71 | 4,137,000 | |
| $7.20 | +0.545 | +8.2% | $6.585 | $7.255 | $6.445 | 2,230,222 | |
| $6.655 | +0.33 | +5.2% | $6.325 | $6.74 | $6.20 | 3,545,000 | |
| $6.325 | +0.025 | +0.4% | $6.795 | $6.795 | $6.14 | 2,555,000 | |
| $6.30 | -0.055 | -0.9% | $6.355 | $6.66 | $6.25 | 1,077,000 | |
| $6.355 | -0.665 | -9.5% | $6.80 | $6.80 | $6.285 | 1,832,000 | |
| $7.02 | +0.45 | +6.8% | $6.68 | $7.18 | $6.555 | 6,655,000 | |
| $6.57 | +0.44 | +7.2% | $6.20 | $6.675 | $6.09 | 1,674,000 | |
| $6.13 | -0.165 | -2.6% | $6.255 | $6.255 | $6.035 | 1,725,000 | |
| $6.295 | +0.105 | +1.7% | $6.21 | $6.425 | $6.13 | 1,460,000 | |
| $6.19 | -0.15 | -2.4% | $6.26 | $6.43 | $6.165 | 1,641,000 | |
| $6.34 | -0.285 | -4.3% | $6.64 | $6.64 | $6.305 | 1,427,000 | |
| $6.625 | +0.075 | +1.1% | $6.675 | $6.95 | $6.55 | 1,874,000 | |
| $6.55 | -0.395 | -5.7% | $6.94 | $6.94 | $6.515 | 2,355,371 | |
| $6.945 | +0.03 | +0.4% | $6.915 | $6.995 | $6.50 | 1,548,000 | |
| $6.915 | -0.12 | -1.7% | $7.00 | $7.35 | $6.765 | 757,897 | |
| $7.035 | -0.505 | -6.7% | $7.54 | $7.805 | $6.91 | 1,386,842 | |
| $7.54 | -0.04 | -0.5% | $7.30 | $7.80 | $7.30 | 2,056,000 | |
| $7.58 | -0.17 | -2.2% | $7.74 | $7.815 | $7.47 | 1,180,000 | |
| $7.75 | +0.48 | +6.6% | $7.60 | $7.955 | $7.475 | 1,841,000 | |
| $7.27 | -0.17 | -2.3% | $7.345 | $7.45 | $7.17 | 2,877,004 | |
| $7.44 | -0.275 | -3.6% | $7.345 | $7.66 | $7.345 | 2,460,000 | |
| $7.715 | +0.015 | +0.2% | $7.63 | $7.73 | $7.315 | 2,047,000 | |
| $7.70 | -0.19 | -2.4% | $8.10 | $8.10 | $7.63 | 1,253,000 | |
| $7.89 | -0.215 | -2.7% | $8.205 | $8.205 | $7.67 | 1,801,000 | |
| $8.105 | -0.555 | -6.4% | $8.90 | $8.90 | $8.10 | 2,025,000 | |
| $8.66 | -0.24 | -2.7% | $8.90 | $8.90 | $8.49 | 511,000 | |
| $8.90 | +0.065 | +0.7% | $9.08 | $9.23 | $8.795 | 581,000 | |
| $8.835 | +0.085 | +1.0% | $8.78 | $8.86 | $8.57 | 468,000 | |
| $8.75 | -0.18 | -2.0% | $8.80 | $8.80 | $8.27 | 811,167 | |
| $8.93 | +0.215 | +2.5% | $8.76 | $9.08 | $8.75 | 1,083,000 | |
| $8.715 | -0.035 | -0.4% | $9.10 | $9.10 | $8.67 | 1,025,000 | |
| $8.75 | -0.21 | -2.3% | $9.01 | $9.025 | $8.71 | 916,720 | |
| $8.96 | -0.06 | -0.7% | $8.995 | $9.30 | $8.72 | 725,000 | |
| $9.02 | -0.24 | -2.6% | $9.26 | $9.26 | $8.805 | 1,525,000 | |
| $9.26 | +0.175 | +1.9% | $9.10 | $9.325 | $8.985 | 801,000 | |
| $9.085 | +0.185 | +2.1% | $8.91 | $9.26 | $8.50 | 856,000 | |
| $8.90 | +0.605 | +7.3% | $8.40 | $8.975 | $8.40 | 1,965,000 | |
| $8.295 | +0.035 | +0.4% | $8.30 | $8.66 | $8.27 | 1,796,196 | |
| $8.26 | +0.025 | +0.3% | $8.52 | $8.52 | $8.155 | 620,000 | |
| $8.235 | -0.275 | -3.2% | $8.75 | $8.80 | $8.135 | 939,000 | |
| $8.51 | -0.195 | -2.2% | $8.705 | $8.715 | $8.45 | 880,000 | |
| $8.705 | +0.185 | +2.2% | $8.49 | $8.705 | $8.255 | 1,113,000 | |
| $8.52 | +0.165 | +2.0% | $8.355 | $8.52 | $8.04 | 2,520,000 | |
| $8.355 | -0.47 | -5.3% | $8.70 | $8.85 | $8.30 | 1,499,730 | |
| $8.825 | -0.12 | -1.3% | $9.195 | $9.195 | $8.635 | 1,052,000 | |
| $8.945 | +0.13 | +1.5% | $8.82 | $9.025 | $8.56 | 626,000 | |
| $8.815 | +0.05 | +0.6% | $9.20 | $9.21 | $8.65 | 568,000 | |
| $8.765 | -0.16 | -1.8% | $9.01 | $9.16 | $8.72 | 1,468,000 | |
| $8.925 | +0.015 | +0.2% | $9.09 | $9.095 | $8.555 | 827,000 | |
| $8.91 | +0.095 | +1.1% | $8.775 | $9.09 | $8.655 | 729,000 | |
| $8.815 | -0.07 | -0.8% | $8.86 | $8.995 | $8.70 | 593,000 | |
| $8.885 | -0.385 | -4.2% | $9.875 | $9.875 | $8.84 | 1,867,000 | |
| $9.27 | -0.58 | -5.9% | $9.80 | $9.80 | $9.195 | 1,597,000 | |
| $9.85 | +0.10 | +1.0% | $10.39 | $10.39 | $9.70 | 1,414,000 | |
| $9.75 | -0.125 | -1.3% | $10.15 | $10.50 | $9.72 | 844,000 | |
| $9.875 | +0.005 | +0.1% | $10.50 | $10.50 | $9.35 | 1,812,900 | |
| $9.87 | -0.45 | -4.4% | $10.37 | $10.37 | $9.76 | 994,000 | |
| $10.32 | -0.28 | -2.6% | $10.98 | $10.98 | $10.20 | 674,000 | |
| $10.60 | +0.40 | +3.9% | $10.45 | $10.88 | $10.45 | 1,676,000 |
- Ticker
- Lang & Schwarz:A3C4Y0
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Lang & Schwarz
- Currency
- EUR
What changed lately
Latest news
VOLUNTARY ANNOUNCEMENT - Abbisko Therapeutics Presents Preclinical Findings on Novel Selective CDK4 Inhibitor ABSK192 in Single-Agent and Combination Studies at 2026 ENA
Nov 18, 2026
Closed $5.68 (-9.8%) on Nov 20, 2026
Voluntary announcement - increase in shareholding of the company by the founder, the executive director, the chief executive officer and the chairman of the board of the company
Nov 11, 2026
Closed $7.20 (+8.2%) on Nov 12, 2026
INSIDE INFORMATION - PIMJETMI (pimicotinib) Receive U.S. FDA Approval for TGCT
Nov 10, 2026
Closed $6.66 (+5.2%) on Nov 11, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
Nov 2, 2026
Closed $6.13 (-2.6%) on Nov 3, 2026
Change of company name
Nov 2, 2026
Closed $6.30 (+1.7%) on Nov 2, 2026
Next Day Disclosure Returns
Oct 30, 2026
Closed $6.30 (+1.7%) on Nov 2, 2026
Abbisko Cayman Limited on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 28 in the last 12 months · 38 in all · newest Nov 19, 2026 · oldest 2021
- Decks
- 7 decks · latest Aug 13, 2024
Where Abbisko Cayman Limited is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| HKEX:2256 和譽 · Home listing | HKEX | Hong Kong | HKD |
| LS Exchange:A3C4Y0 | LS Exchange | Germany | EUR |
| Lang & Schwarz:A3C4Y0 · This page | Lang & Schwarz | Germany | EUR |
| Frankfurt:8ZD | Frankfurt | Germany | EUR |
| Dusseldorf:8ZD | Dusseldorf | Germany | EUR |
| Stuttgart:8ZD | Stuttgart | Germany | EUR |
Valuation
Price/book 1.6× against a median of 2.2×: 5th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $1.79B HKD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.6×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.2×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Abbisko Cayman Limited · HKEX:2256 | US$518.9M | US$228.0M | n/a | n/a | n/a | 1.6× | n/a | 0.2× | n/a |
| Aclaris Therapeutics, Inc. · NASDAQ:ACRS | US$545.6M | US$431.3M | n/a | 67.4× | n/a | 3.3× | n/a | 0.0× | 1.42 |
| ArriVent BioPharma, Inc. · NASDAQ:AVBP | US$544.1M | US$151.2M | n/a | 30.2× | n/a | 1.4× | n/a | 0.0× | 1.18 |
| Surrozen, Inc. · NASDAQ:SRZN | US$542.5M | US$448.0M | n/a | 42.5× | n/a | n/a | n/a | n/a | 1.64 |
| Climb Bio, Inc. · NASDAQ:CLYM | US$539.8M | US$335.4M | n/a | n/a | n/a | 2.4× | n/a | 0.0× | 1.44 |
| Alumis Inc. · NASDAQ:ALMS | US$512.6M | US$116.5M | n/a | 16.1× | n/a | 1.4× | n/a | 0.1× | 1.58 |
| Electra Therapeutics, Inc. · NASDAQ:ETRA | US$509.8M | US$107.3M | n/a | n/a | n/a | 1.3× | n/a | 0.0× | n/a |
| Wave Life Sciences Ltd. · NASDAQ:WVE | US$504.9M | US$74.16M | n/a | 1.1× | n/a | 1.3× | −296.9% | 0.0× | 1.70 |
| Adlai Nortye Group Ltd. · NASDAQ:ANL | US$502.2M | US$297.0M | n/a | 59.4× | n/a | 2.3× | −710.6% | 0.1× | 1.96 |
| Steminent Biotherapeutics, Inc. · TPEX:7729 | US$496.9M | US$470.4M | n/a | n/a | n/a | 16.2× | n/a | 0.0× | n/a |
| Xuanzhu Biopharmaceutical Co., Ltd. Class H · HKEX:2575 | US$495.2M | US$407.1M | n/a | 23.2× | n/a | 2.2× | −200.8% | 0.0× | n/a |
| Median of the others | US$511.2M | US$316.2M | 30.2× | 2.2× | −296.9% | 0.0× | 1.58 |
Forecasts
Analysts' consensus from EODHD, read Nov 22, 2026. Not 6ix's view and not investment advice.
- Price target
- 19.35 HKD · Analysts' mean
- EPS, year to Dec 2026
- -0.54 · 6 analysts
- Revenue, year to Dec 2026
- 284.4M · 5 analysts
Team and board
| Officer | Role |
|---|---|
| Yao-Chang Xu | Founder & CEO |
| Jia FENG | VP, HR and Operations |
| Zhen ZHANG | CMC VP |
| Hongping Yu | Co-founder, CSO |
| Jing JI | Chief Medical Officer |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q2 2025 | Sep 15, 2025 | −6.1% |
| Q1 2025 | Jun 18, 2025 · Before open | +2.9% |
| Q4 2022 | Mar 14, 2023 · After close | +6.7% |
| Q2 2022 | Sep 27, 2022 · After close | −2.7% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Abbisko Therapeutics — H1 2024 Earnings Presentation | Earnings | 32 slides | Aug 13, 2024 |
| Abbisko Therapeutics — FY2023 Earnings Presentation | Earnings | 38 slides | Mar 13, 2024 |
| Abbisko Therapeutics — Investor Presentation (March 2024) | Investor deck | 39 slides | March 2024 |
| Abbisko Therapeutics — H1 2023 Earnings Presentation | Earnings | 32 slides | August 2023 |
| Abbisko Therapeutics — FY2022 Earnings Presentation | Earnings | 31 slides | Mar 16, 2023 |
| Abbisko Therapeutics — H1 2022 Earnings Presentation | Earnings | 18 slides | August 2022 |
| Abbisko Therapeutics — FY2021 Earnings Presentation | Earnings | 40 slides | Mar 21, 2022 |
Financials
Annual, in CNY
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 596.3M | 504.0M | 19.1M | 0 | 22.7M | 0 | 3.84M |
| Cost of revenue | 0 | 0 | 0 | 0 | 0 | 0 | |
| Gross profit | 596.3M | 504.0M | 19.1M | 0 | 22.7M | 0 | 3.84M |
| Research and development | 495.3M | 451.4M | 433.7M | 378.7M | 226.1M | 132.7M | 81.5M |
| Selling, general and administrative | 75.8M | 74.2M | 35.6M | 29.8M | 54.8M | 9.11M | 12.1M |
| Operating income | 27.2M | -21.6M | -511.1M | -497.2M | -328.2M | -153.8M | -134.1M |
| Depreciation and amortization | 22.3M | 23.6M | 18.4M | 15.8M | 11.9M | 9.49M | 8.19M |
| EBITDA | 49.5M | 1.98M | -492.7M | -481.4M | -316.3M | -144.3M | -125.9M |
| Interest expense | 3.25M | 1.61M | 2.17M | 2.69M | 959.0K | 338.0K | 523.0K |
| Income before tax | 113.4M | 78.0M | -431.6M | -495.6M | -1.81B | -706.6M | -133.9M |
| Income tax | 59.6M | 49.7M | 2.69M | -4.94M | 172.0K | -221.0K | |
| Net income | 53.8M | 28.3M | -431.6M | -498.3M | -1.81B | -706.8M | -133.7M |
| Earnings per share, basic | 0.08 | 0.04 | -0.67 | -0.80 | -7.68 | -1.01 | -0.19 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 749.3M | 289.5M | 578.1M | 2.26B | 2.55B | 617.8M | 285.6M |
| Short-term investments | 1.35B | 1.67B | 918.0K | 93.8M | 26.5M | 18.9M | 11.4M |
| Receivables | 15.0M | 47.7M | 17.8M | 9.12M | 39.0K | ||
| Current assets | 2.13B | 2.02B | 2.04B | 2.41B | 2.58B | 649.8M | 300.2M |
| Property, plant and equipment | 69.3M | 77.3M | 69.3M | 14.8M | 20.1M | ||
| Total assets | 2.35B | 2.11B | 2.12B | 2.49B | 2.65B | 666.0M | 320.2M |
| Current liabilities | 427.3M | 135.4M | 109.2M | 107.6M | 73.5M | 31.7M | 17.8M |
| Long-term debt | 0 | 1.72B | 758.0M | ||||
| Total debt | 303.6M | 24.3M | 35.7M | 45.6M | 53.8M | 4.31M | 8.90M |
| Total liabilities | 430.4M | 148.7M | 134.3M | 143.2M | 118.5M | 1.77B | 779.3M |
| Shareholders' equity | 1.92B | 1.96B | 1.98B | 2.35B | 2.54B | -1.10B | -459.0M |
| Shares outstanding | 639.8M | 649.6M | 647.2M | 620.7M | 234.9M | 702.5M | 702.5M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | 79.3M | -12.9M | -444.7M | -343.9M | -169.7M | -117.6M | -82.8M |
| Capital spending | -5.53M | -7.40M | -12.3M | -22.7M | -12.3M | -4.03M | -3.44M |
| Free cash flow | 73.8M | -20.3M | -457.0M | -366.6M | -182.1M | -121.6M | -86.3M |
| Cash from investing | 211.9M | -196.5M | 378.5M | -216.6M | -1.46B | -11.2M | 30.1M |
| Cash from financing | 186.9M | -80.9M | -16.1M | -20.8M | 2.10B | 505.9M | 176.9M |
| Share buybacks | -96.2M | -76.3M | -12.9M | -4.05M | 1.45B | 511.0M | 182.6M |
| Change in cash | 459.5M | -288.6M | -63.8M | -422.0M | 446.1M | 332.1M | 131.8M |
Filings
All 25 filings
Cap table
Built by 6ix from Abbisko Cayman Limited’s releases
- Common shares
- 716,157,350
- Fully diluted
- 716,157,350
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 716,157,350 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 716,157,350 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Hongping Yu | Co-founder, CSO · Since at least Nov 5, 2026 |
| Jia FENG | VP, HR and Operations · Since at least Nov 5, 2026 |
| Jing JI | Chief Medical Officer · Since at least Nov 5, 2026 |
| Yao-Chang Xu | Founder & CEO · Since at least Jun 10, 2025 |
| Zhen ZHANG | CMC VP · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Abbisko Cayman Limited.